Science

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Patrick Forde/Facebook

Mar 11, 2025, 13:12

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, shared an article by Anwen Xiong, et al. on X:

“Now published!

PD-1 VEGF bispecific doubles PFS in 1st line advanced non-small cell lung cancer.

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China – The Lancet.”

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Authors: Anwen Xiong, et al.

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Anwen Xiong cancer China fight against cancer Global fight against cancer HARMONi-2 ivonescimab Johns Hopkins University non small cell lung cancer NSCLC OncoDaily Oncology Patrick Forde pembrolizumab Sidney Kimmel Comprehensive Cancer Center The Lancet

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage